STOCK TITAN
  1. Home
  2. News
  3. PVCT

PROVECTUS BIOPHARMS - $PVCT STOCK NEWS

Welcome to our dedicated page for PROVECTUS BIOPHARMS news (Ticker: $PVCT), a resource for investors and traders seeking the latest updates and insights on PROVECTUS BIOPHARMS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PROVECTUS BIOPHARMS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PROVECTUS BIOPHARMS's position in the market.

News
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
Rhea-AI Summary
Provectus (PVCT) has received patent approval from the USPTO for the use of its rose bengal sodium (RBS) drug substance as an adjuvant in vaccines. The patent covers the potential use in anticancer, antiviral, and other vaccines, with the potential to enhance T-cell response. The research underlying the patent was led by Dr. Aru Narendran and his lab team, with promising preclinical data presented at the SITC 2023 annual meeting. The patent award marks Provectus's first in the field of vaccines from the USPTO, with Innovate Calgary as a co-assignee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.6%
Tags
none
-
News
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
Rhea-AI Summary
Provectus (OTCQB: PVCT) provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 in combination with standard of care immune checkpoint blockade for advanced cutaneous melanoma. Initial results from CB-naïve patients in the main study cohort showed potential clinical benefit across all stages of metastasis. Longer-term follow-up of an expanded patient population has been assessed, revealing promising outcomes. The primary endpoint of the Phase 1b portion was safety and tolerability, with objective response rate (ORR) and progression-free survival (PFS) as key secondary endpoints. Treatment-emergent adverse events were consistent with established patterns of both study drugs. For all CB-naïve patients, the ORR was 72%, with a median PFS of 12.5 months and a median overall survival (mOS) of 37.6 months. For CB-naïve Stage III patients, the ORR was 83%, with rapid and durable complete responses and estimated mOS and median disease-specific survival (mDSS) of 36.3 months and 42.5 months, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
-
News
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
Rhea-AI Summary
Provectus (OTCQB: PVCT) provides updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 for the treatment of uveal melanoma metastatic to the liver. The data shows acceptable safety, objective response rates, and median overall survival, with positive outcomes for patients receiving PV-10, either as monotherapy or in combination with immune checkpoint blockade (CB). The company plans to expand the study to confirm the initial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.43%
Tags
none
News
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Rhea-AI Summary
Provectus announces preclinical data on the potential use of PV-10 as an adjuvant in vaccines. The research shows PV-10's ability to enhance T-cell responses and improve immune response to vaccination. PV-10 could be used in anti-viral, anti-cancer, and other vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
none
-
News
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
-
News
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.34%
Tags
none
News
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
News
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
News
Provectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative Bacteria
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
none
News
Provectus Biopharmaceuticals Releases 2023 Stockholder Letter
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.8%
Tags
none
Stock PVCT logo
PROVECTUS BIOPHARMS

OTC:PVCT

PVCT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PVCT Stock Data

70.23M
385.53M
9.42%
0.06%
0.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Knoxville

About PVCT

provectus biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. provectus’ investigational oncology drug, pv-10, is an ablative immunotherapy under investigation in solid tumor cancers.